Works matching DE "OSIMERTINIB"
Results: 307
Metabolism and pharmacokinetic study of deuterated osimertinib.
- Published in:
- Biopharmaceutics & Drug Disposition, 2023, v. 44, n. 2, p. 165, doi. 10.1002/bdd.2347
- By:
- Publication type:
- Article
Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats.
- Published in:
- PeerJ, 2023, p. 1, doi. 10.7717/peerj.15844
- By:
- Publication type:
- Article
Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFR<sup>WT/</sup>EGFR<sup>T790M</sup> inhibitors.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2023, v. 38, n. 1, p. 1, doi. 10.1080/14756366.2023.2218602
- By:
- Publication type:
- Article
Osimertinib-Induced Toxic Epidermal Necrolysis – A Case Report.
- Published in:
- Contributions / Prilozi (1857-9345), 2024, v. 45, n. 3, p. 77, doi. 10.2478/prilozi-2024-0025
- By:
- Publication type:
- Article
Solubilization, Hansen solubility parameters and apparent thermodynamic parameters of Osimertinib in (propylene glycol + water) cosolvent mixtures.
- Published in:
- Zeitschrift für Physikalische Chemie, 2021, v. 235, n. 8, p. 977, doi. 10.1515/zpch-2020-1719
- By:
- Publication type:
- Article
Leukocytes telomere length as a biomarker of adverse drug reactions induced by Osimertinib in advanced non-small cell lung cancer.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-77935-0
- By:
- Publication type:
- Article
MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinoma.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-76196-1
- By:
- Publication type:
- Article
Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.
- Published in:
- Biomolecules (2218-273X), 2021, v. 11, n. 5, p. 618, doi. 10.3390/biom11050618
- By:
- Publication type:
- Article
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 41, doi. 10.2147/LCTT.S453974
- By:
- Publication type:
- Article
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 79, doi. 10.2147/LCTT.S431252
- By:
- Publication type:
- Article
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib.
- Published in:
- Lung Cancer: Targets & Therapy, 2022, v. 13, p. 23, doi. 10.2147/LCTT.S358902
- By:
- Publication type:
- Article
Drug-induced lupus induced by osimertinib (Tagrisso): A case report.
- Published in:
- Our Dermatology Online / Nasza Dermatologia Online, 2025, v. 16, n. 1, p. 87, doi. 10.7241/ourd.20251.18
- By:
- Publication type:
- Article
Synergistic Anti-Tumor Efficacy Achieved by Reversing Drug Resistance through the Regulation of the Tumor Immune Microenvironment with IL-12 and Osimertinib Combination Therapy.
- Published in:
- Journal of Cancer, 2024, v. 15, n. 14, p. 4534, doi. 10.7150/jca.95407
- By:
- Publication type:
- Article
Hsa_circ_0007312 Promotes Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance through Pyroptosis and Apoptosis via the MiR-764/MAPK1 Axis in Lung Adenocarcinoma Cells.
- Published in:
- Journal of Cancer, 2022, v. 13, n. 9, p. 2798, doi. 10.7150/jca.72066
- By:
- Publication type:
- Article
Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
- Published in:
- Radiation Oncology, 2021, v. 16, n. 1, p. 1, doi. 10.1186/s13014-021-01955-7
- By:
- Publication type:
- Article
Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms.
- Published in:
- Clinical Respiratory Journal, 2024, v. 18, n. 10, p. 1, doi. 10.1111/crj.70025
- By:
- Publication type:
- Article
The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis.
- Published in:
- Clinical Respiratory Journal, 2024, v. 18, n. 4, p. 1, doi. 10.1111/crj.13748
- By:
- Publication type:
- Article
Successful dacomitinib treatment after osimertinib resistance in a patient with lung adenocarcinoma.
- Published in:
- Clinical Respiratory Journal, 2021, v. 15, n. 7, p. 851, doi. 10.1111/crj.13360
- By:
- Publication type:
- Article
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer.
- Published in:
- Cancer Cell International, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12935-021-02075-8
- By:
- Publication type:
- Article
SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness.
- Published in:
- Cancer Cell International, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12935-021-02056-x
- By:
- Publication type:
- Article
Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7.
- Published in:
- Molecular Cancer, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12943-023-01811-0
- By:
- Publication type:
- Article
Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer.
- Published in:
- Molecular Cancer, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12943-022-01662-1
- By:
- Publication type:
- Article
Successful treatment of epidermal growth factor receptor exon 19 deletion non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: A case report.
- Published in:
- Journal of Cancer Research & Therapeutics, 2024, v. 20, n. 7, p. 2148, doi. 10.4103/jcrt.jcrt_2235_24
- By:
- Publication type:
- Article
Expert opinion on adjuvant treatment with osimertinib in patients with non-small cell lung carcinoma after radical tumor resection.
- Published in:
- Nowotwory, 2023, v. 73, n. 3, p. 187, doi. 10.5603/njo.96212
- By:
- Publication type:
- Article
Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study.
- Published in:
- Biomedicines, 2024, v. 13, n. 7, p. 1412, doi. 10.3390/biomedicines12071412
- By:
- Publication type:
- Article
A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety.
- Published in:
- Biomedicines, 2023, v. 11, n. 9, p. 2501, doi. 10.3390/biomedicines11092501
- By:
- Publication type:
- Article
UBL3 Interacts with Alpha-Synuclein in Cells and the Interaction Is Downregulated by the EGFR Pathway Inhibitor Osimertinib.
- Published in:
- Biomedicines, 2023, v. 11, n. 6, p. 1685, doi. 10.3390/biomedicines11061685
- By:
- Publication type:
- Article
PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC).
- Published in:
- Biomedicines, 2022, v. 10, n. 8, p. N.PAG, doi. 10.3390/biomedicines10081893
- By:
- Publication type:
- Article
P8‐160: The steroids worked well on the Steven‐Johnson syndrome caused by osimertinib in a patient with EGFR mutation‐positive (exon 19 deletion) non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 351, doi. 10.1111/resp.14150_672
- Publication type:
- Article
P8‐120: Therapeutic efficacy of osimertinib following afatinib for the rare EGFR mutation exon19 delL747_P753insS: A case report.
- Published in:
- Respirology, 2021, v. 26, p. 335, doi. 10.1111/resp.14150_632
- Publication type:
- Article
P8‐114: Impact of clinical features on two‐year survival in T790M mutant NSCLC treated with osimertinib.
- Published in:
- Respirology, 2021, v. 26, p. 332, doi. 10.1111/resp.14150_626
- Publication type:
- Article
P8‐99: Efficacy of repeat re‐biopsy and osimertinib in patients with EGFR mutation positive advanced NSCLC.
- Published in:
- Respirology, 2021, v. 26, p. 327, doi. 10.1111/resp.14150_611
- Publication type:
- Article
P8‐93: Relationship between efficacy of afatinib and plasma EGFR mutation in osimertinib‐resistant patients with EGFR mutated lung cancer; NJLCG1801B study.
- Published in:
- Respirology, 2021, v. 26, p. 325, doi. 10.1111/resp.14150_605
- Publication type:
- Article
P8‐62: A phase II trial of osimertinib for elderly patients with epidermal growth factor receptor T790M‐positive non‐small cell lung cancer that progressed during previous treatment.
- Published in:
- Respirology, 2021, v. 26, p. 311, doi. 10.1111/resp.14150_574
- Publication type:
- Article
P8‐33: A case of enterocolitis with bleeding caused by osimertinib.
- Published in:
- Respirology, 2021, v. 26, p. 300, doi. 10.1111/resp.14150_545
- Publication type:
- Article
P8‐31: Prospective observational study of sequential afatinib and osimertinib in NSCLC patients with EGFR mutation: Gio‐Tag Japan.
- Published in:
- Respirology, 2021, v. 26, p. 299, doi. 10.1111/resp.14150_543
- Publication type:
- Article
P8‐29: Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in EGFR‐mutant NSCLC with T790M mutation.
- Published in:
- Respirology, 2021, v. 26, p. 298, doi. 10.1111/resp.14150_541
- Publication type:
- Article
P8‐23: Clinical importance of LINC00460 expression in EGFR mutation‐positive lung cancer treated with osimertinib.
- Published in:
- Respirology, 2021, v. 26, p. 296, doi. 10.1111/resp.14150_535
- Publication type:
- Article
P8‐16: An exploratory study of biomarkers in blood of osimertinib for EGFR‐T790M mutation‐positive NSCLC.
- Published in:
- Respirology, 2021, v. 26, p. 293, doi. 10.1111/resp.14150_528
- Publication type:
- Article
O13‐3: The ratio of T790M to EGFR‐activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR‐TKI‐refractory NSCLC.
- Published in:
- Respirology, 2021, v. 26, p. 36, doi. 10.1111/resp.14149_76
- Publication type:
- Article
P8‐160: The steroids worked well on the Steven‐Johnson syndrome caused by osimertinib in a patient with EGFR mutation‐positive (exon 19 deletion) non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 351, doi. 10.1111/resp.14150_672
- Publication type:
- Article
P8‐120: Therapeutic efficacy of osimertinib following afatinib for the rare EGFR mutation exon19 delL747_P753insS: A case report.
- Published in:
- Respirology, 2021, v. 26, p. 335, doi. 10.1111/resp.14150_632
- Publication type:
- Article
P8‐114: Impact of clinical features on two‐year survival in T790M mutant NSCLC treated with osimertinib.
- Published in:
- Respirology, 2021, v. 26, p. 332, doi. 10.1111/resp.14150_626
- Publication type:
- Article
P8‐99: Efficacy of repeat re‐biopsy and osimertinib in patients with EGFR mutation positive advanced NSCLC.
- Published in:
- Respirology, 2021, v. 26, p. 327, doi. 10.1111/resp.14150_611
- Publication type:
- Article
P8‐93: Relationship between efficacy of afatinib and plasma EGFR mutation in osimertinib‐resistant patients with EGFR mutated lung cancer; NJLCG1801B study.
- Published in:
- Respirology, 2021, v. 26, p. 325, doi. 10.1111/resp.14150_605
- Publication type:
- Article
P8‐62: A phase II trial of osimertinib for elderly patients with epidermal growth factor receptor T790M‐positive non‐small cell lung cancer that progressed during previous treatment.
- Published in:
- Respirology, 2021, v. 26, p. 311, doi. 10.1111/resp.14150_574
- Publication type:
- Article
P8‐33: A case of enterocolitis with bleeding caused by osimertinib.
- Published in:
- Respirology, 2021, v. 26, p. 300, doi. 10.1111/resp.14150_545
- Publication type:
- Article
P8‐31: Prospective observational study of sequential afatinib and osimertinib in NSCLC patients with EGFR mutation: Gio‐Tag Japan.
- Published in:
- Respirology, 2021, v. 26, p. 299, doi. 10.1111/resp.14150_543
- Publication type:
- Article
P8‐29: Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in EGFR‐mutant NSCLC with T790M mutation.
- Published in:
- Respirology, 2021, v. 26, p. 298, doi. 10.1111/resp.14150_541
- Publication type:
- Article
P8‐23: Clinical importance of LINC00460 expression in EGFR mutation‐positive lung cancer treated with osimertinib.
- Published in:
- Respirology, 2021, v. 26, p. 296, doi. 10.1111/resp.14150_535
- Publication type:
- Article